Trial Profile
A Study to Evaluate the Efficay and Safety of Ledipasvir/sofosbuvir With or Without Ribavirin in Hepatitis C Genotype 1 Patients who Failed Previous Treatment with Simeprevir plus Sofosbuvir
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Mar 2016
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 10 Mar 2016 New trial record